Article | December 18, 2023

What The FDA And EMA Discussion Papers Reveal About AI In Clinical Research

Source: Castor
GettyImages-1474595785 AI

The integration of artificial intelligence (AI) into clinical processes, when coupled with effective human oversight, has the potential to significantly enhance efficiency. One notable impact is the acceleration of study development as AI-assisted solutions streamline and expedite repetitive and time-consuming tasks for research teams. Despite these advancements, a critical challenge lies in the absence of standardized practices for AI, hindering the ability to mitigate both real and perceived risks and ensure the safety, compliance, and predictability of AI applications.

The ongoing discourse surrounding the standardization of AI for secure implementation in clinical research has gained momentum. Recent discussion papers on AI in drug development released by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) mark regulatory bodies' active participation in shaping this dialogue. Importantly, these publications serve as catalysts for discussions within the research community, emphasizing the need to optimize AI use in drug development while safeguarding patient well-being.

Learn how having a comprehensive understanding of regulatory perspectives on AI ethics will prove invaluable for researchers evaluating the integration of AI technology into their trials by accessing the article below.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader